Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EPS (Weighted Average and Diluted) (2019 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.73 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 1.39% to -$0.73 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.11 through Dec 2025, up 28.51% year-over-year, with the annual reading at -$3.11 for FY2025, 28.34% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.73 at Rhythm Pharmaceuticals, up from -$0.82 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.9 in Q1 2021, with the low at -$2.35 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.77, with a median of -$0.76 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 215.38% in 2021, then plummeted 216.67% in 2022.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.86 in 2021, then increased by 13.95% to -$0.74 in 2022, then increased by 5.41% to -$0.7 in 2023, then dropped by 2.86% to -$0.72 in 2024, then dropped by 1.39% to -$0.73 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.73, -$0.82, and -$0.75 for Q4 2025, Q3 2025, and Q2 2025 respectively.